Linked Data API

Show Search Form

Search Results

1714027
star this property registered interest false more like this
star this property date less than 2024-04-26more like thismore than 2024-04-26
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Evusheld more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19. more like this
star this property tabling member constituency Christchurch more like this
star this property tabling member printed
Sir Christopher Chope more like this
star this property uin 23829 remove filter
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2024-05-01more like thismore than 2024-05-01
star this property answer text <p>The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p>
star this property answering member constituency Pendle more like this
star this property answering member printed Andrew Stephenson more like this
star this property question first answered
less than 2024-05-01T08:57:40.253Zmore like thismore than 2024-05-01T08:57:40.253Z
star this property answering member
4044
star this property label Biography information for Andrew Stephenson more like this
star this property tabling member
242
star this property label Biography information for Sir Christopher Chope more like this